Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548925 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00548925 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 124 participants.
The verdict
NCT00548925, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a 6 mg twice a day dose of an investigational product in subjects with diabetic neuropathy
Interventions
- DRUG placebo
- DRUG ABT-894
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548925
The ClinicalTrials.gov registry entry for NCT00548925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00548925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548925 about?
NCT00548925 is a clinical study titled "A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain". The purpose of this study is to evaluate the safety and efficacy of a 6 mg twice a day dose of an investigational product in subjects with diabetic neuropathy
What is the current status of trial NCT00548925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2007-11. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00548925?
The interventions under investigation include: placebo (DRUG), ABT-894 (DRUG).
Who is sponsoring clinical trial NCT00548925?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.